Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by hmmmmmmmmon Feb 23, 2023 1:13pm
246 Views
Post# 35301243

1 patient every 21 days..

1 patient every 21 days..That's the big take away form the update.

Over the last 3 years- 1 patient every 21 days.

(But Covid) Well, the numbers have actually been worse since..

Since the Nov 10th update- 1 patient every 26 days.

You would think this would be a 3 alarm fire for Spectral's management- at this rate it will take almost 7 years to reach the 150 patients required.

Nope.
 
During this time Kellum stated:

"We have witnessed an approximate 50% increase in ICU sepsis cases." (Nov 10)

"This influx of sepsis cases combined with the additional clinical trial sites has improved screening activities as well as accelerated enrollment. " (Nov 10)

 "we are witnessing a significant increase in enrollment activities." (Jan 12)

"In particular, patient enrolment ramped up during late Q3 and for most of Q4,"
(Jan 12)

"As a result, we added approximately 30% of our total enrollment target in the second half of 2022 alone." (Jan 12)

"Given our progress, we are nearing our interim enrollment target of 90 patients."
(Jan 12)

"Flu season is upon us and as influenza cases rise, we believe sepsis cases will concurrently increase," (Jan 12)


And Seto added:
“We are making steady headway with our Tigris trial" (Nov 10)

"We are witnessing stable recruitment levels across our Tigris clinical trial sites"
(Nov 10)

"We continue to aggressively advance our Tigris trial" (Jan 12)


But, in reality only 4 patients were added the last 105 days.

You read their statements you have to ask yourself-  Will they just say anything? 
What happened to integrity?
Or even worse- are they actually fine with their enrollment? a rate that would take almost 7 years to complete.

Dr. Walker and the board must take control of the ship.
This is not sustainable.
<< Previous
Bullboard Posts
Next >>